Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CT 001 - Coagulant Therapeutics

Next Previous
Drug Profile

CT 001 - Coagulant Therapeutics

Alternative Names: CT-001 - Coagulant Therapeutics

Latest Information Update: 10 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Coagulant Therapeutics
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor VIIa replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postpartum haemorrhage
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Postpartum haemorrhage

Most Recent Events

  • 10 Jul 2023 Coagulant therapeutics plans for IND submission for Postpartum haemorrhage (Coagulant therapeutics pipeline July 2023)
  • 10 Dec 2022 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Postpartum haemorrhage presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-2022)
  • 11 Jul 2022 CT 001 - Coagulant Therapeutics is available for licensing as of 11 Jul 2022. https://www.coagulanttherapeutics.com/partner

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top